YesidAlvarado ValeroMD

PubMed

• 2 citations
  Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
  Sangeetha Venugopal, Abhishek Maiti, Courtney D. DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi, Naval Daver, Tapan M. Kadia, Caitlin R. Rausch, Yesid Alvarado, Maro Ohan...> ;Leukemia & Lymphoma. 2021 Sep 3
• 22 citations
  Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
  Abhishek Maiti, Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias J. Jabbour, Caitlin R. Rausch, Naval Daver, Nicholas J. Short, Gautam Borthakur, Naveen Pemmaraju,...> ;Cancer. 2021 Nov 15
• 30 citations
  Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
  Kelly S. Chien, Kunhwa Kim, Graciela M. Nogueras-Gonzalez, Gautam Borthakur, Kiran Naqvi, Naval Daver, Guillermo Montalban-Bravo, Jorge E. Cortes, Courtney D. DiNardo,...> ;British Journal of Haematology. 2021 Aug 2
• 67 citations
  Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplasti...
  Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur, Musa Yilmaz, Steven M. Kornblau, Yesid Alvarado, Courtney D. DiNardo, Naval Daver, Nitin Jain, Naveen Pemmaraju, ...> ;The Lancet. Haematology. 2021 Aug 1
• 73 citations
  Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
  Kunhwa Kim, Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch, Ken Furudate, Naval Daver, Yesid Alvarado, Maro Ohanian, Koji Sasaki,...> ;Cancer. 2021 Oct 15
• 42 citations
  Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
  Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev Estrov, Koji Sasaki, Nathan Fowler, T...> ;JAMA Oncology. 2021 Aug 1
• 136 citations
  Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
  Courtney D. DiNardo, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Lianchun Xiao, Tapan M. Kadia, Naval Daver, Maria Adeoti, Nicholas J. Short, Koji Sasaki, Sa Wa...> ;Journal of Clinical Oncology. 2021 May 27
• 30 citations
  Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
  Curtis Lachowiez, Sanam Loghavi, Ken Furudate, Guillermo Montalban-Bravo, Abhishek Maiti, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Koji Sasaki,...> ;Blood Advances. 2021 Apr 27
• 24 citations
  A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplas...
  Mahesh Swaminathan, Hagop M. Kantarjian, Mark J. Levis, Veronica A Guerra, Gautam Borthakur, Yesid Alvarado, Courtney D. DiNardo, Tapan M. Kadia, Guillermo Garcia-Mane...> ;Haematologica. 2021 Apr 15
• 28 citations
  Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
  Caitlin R. Rausch, Courtney D. DiNardo, Abhishek Maiti, Nadya Jammal, Tapan M. Kadia, Kayleigh Marx, Gautam Borthakur, J. Michael Savoy, Naveen Pemmaraju, Adam J. DiPi...> ;Cancer. 2021 Jul 15
• 22 citations
  Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia...
  Elias Jabbour, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Joseph D. Khoury, Rashmi Kanagal-Shamanna, Jeffrey L. Jorgensen, Issa F. Khouri, Partow Ke...> ;Cancer. 2021 Jun 15
• 19 citations
  Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.
  Patrick K. Reville, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver, Naveen Pemmaraju, Maro Ohanian, Yesid Alvarado, Lianchun Xiao...> ;Blood Cancer Journal. 2021 Mar 17
• 54 citations
  Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
  Abhishek Maiti, Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Sherry Pierce, Kathryn S....> ;American Journal of Hematology. 2021 Mar 1
• 19 citations
  Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
  Sangeetha Venugopal, Abhishek Maiti, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Tapan M. Kadia, Caitlin R. Rausch, Yesid Alvarado, Maro Ohanian, Koji Sasaki, Nic...> ;American Journal of Hematology. 2021 Feb 13
• 35 citations
  Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.
  Sarah A. Bannon, Mark J. Routbort, Guillermo Montalban-Bravo, Rohtesh S. Mehta, Fatima Zahra Jelloul, Koichi Takahashi, Naval Daver, Betul Oran, Naveen Pemmaraju, Gaut...> ;Frontiers in Oncology. 2021 Jan 28
• 35 citations
  Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.
  Helen T. Chifotides, Lucia Masarova, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. Di...> ;Blood Advances. 2020 Nov 10
• 175 citations
  10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 t...
  Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Gha...> ;The Lancet. Haematology. 2020 Sep 5
• 35 citations
  Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-...
  Elias Jabbour, Guillaume Richard-Carpentier, Yuya Sasaki, Marina Konopleva, Keyur P. Patel, Kathryn G. Roberts, Zhaohui Gu, Feng Wang, Xuelin Huang, Koji Sasaki, Nicho...> ;The Lancet. Haematology. 2020 Jul 1
• 15 citations
  Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
  Shyamala C. Navada, Guillermo Garcia-Manero, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado, Maro Ohanian, Rosmy B. John, Erin P. Demakos, Patrick S. Zbysz...> ;Leukemia Research. 2020 May 12
• 7 citations
  Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
  Koji Sasaki, Hagop M. Kantarjian, William G. Wierda, Farhad Ravandi-Kashani, Jeffrey L. Jorgensen, Sa A. Wang, Joseph D. Khoury, Naval Daver, Jan A. Burger, Courtney D...> ;American Journal of Hematology. 2020 Jul 1
• 7 citations
  Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
  Ghayas C. Issa, Hagop M. Kantarjian, Lianchun Xiao, Jing Ning, Yesid Alvarado, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour, Prithviraj Bose, Niti...> ;Leukemia. 2020 Jun 16
• 10 citations
  Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia
  Farhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, Tapan M. Kadia, Elias Jabbour, Gautam Borthakur, Courtney D. DiNardo, Naval Daver, Nicholas J. Short, Yesid Alv...> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Nov 29
• 65 citations
  Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
  Abhishek Maiti, Caitlin R. Rausch, Jorge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Kiran Naqvi, Maro Ohanian...> ;Haematologica. 2020 Jun 4
• 98 citations
  Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
  Curtis Lachowiez, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Kiran Naqvi, Yesid Alvarado, Musa Yilmaz, Nicholas J. Short, Maro Oha...> ;Blood Advances. 2020 Apr 14
• 4 citations
  Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes
  Guillermo Garcia-Manero, Naveen Pemmaraju, Yesid Alvarado, Kiran Naqvi, Farhad Ravandi, Elias Jabbour, Ricardo De Lumpa, Hagop M. Kantarjian, Anjali S. Advani, Sudipto...> ;Leukemia & Lymphoma. 2020 Apr 7
• Join now to see all

Abstracts/Posters

• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome
  Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all